RAAFT-2: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation

Authors

  • Riyaz A Kaba 1. Ashford & St Peter's Hospitals NHS Foundation Trust, Chertsey, UK 2. Epsom General Hospital NHS Trust, Epsom, UK 3. St George's Hospital NHS Trust, London, UK 4. Royal Holloway, University of London, UK
  • Douglas Cannie 2. Epsom General Hospital NHS Trust, Epsom, UK
  • Omar Ahmed 1. Ashford & St Peter's Hospitals NHS Foundation Trust, Chertsey, UK

Abstract

Radiofrequency ablation (RFA) for the treatment of paroxysmal Atrial Fibrillation (pAF) has a class 1 indication in patients who have not tolerated or responded to antiarrhythmic medications. Antiarrhythmic medications (AAM) are, however, limited not only by modest efficacy, but also by significant side effects. Discontinuation rates for AAM range from 11-40% in trials. The RAAFT-2 trial evaluates the use of RFA as a first line treatment for pAF compared to optimal pharmacological management.

Downloads

Published

2017-06-28

Issue

Vol. 2014 No. 2 (2014)

Section

Lessons from the trials

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.